Skip to main content
Journal cover image

Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.

Publication ,  Journal Article
Messiaen, L; Yao, S; Brems, H; Callens, T; Sathienkijkanchai, A; Denayer, E; Spencer, E; Arn, P; Babovic-Vuksanovic, D; Bay, C; Bobele, G ...
Published in: JAMA
November 18, 2009

CONTEXT: Autosomal dominant inactivating sprouty-related EVH1 domain-containing protein 1 (SPRED1) mutations have recently been described in individuals presenting mainly with café au lait macules (CALMs), axillary freckling, and macrocephaly. The extent of the clinical spectrum of this new disorder needs further delineation. OBJECTIVE: To determine the frequency, mutational spectrum, and phenotype of neurofibromatosis type 1-like syndrome (NFLS) in a large cohort of patients. DESIGN, SETTING, AND PARTICIPANTS: In a cross-sectional study, 23 unrelated probands carrying a SPRED1 mutation identified through clinical testing participated with their families in a genotype-phenotype study (2007-2008). In a second cross-sectional study, 1318 unrelated anonymous samples collected in 2003-2007 from patients with a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 germline mutation underwent SPRED1 mutation analysis. MAIN OUTCOME MEASURES: Comparison of aggregated clinical features in patients with or without a SPRED1 or NF1 mutation. Functional assays were used to evaluate the pathogenicity of missense mutations. RESULTS: Among 42 SPRED1-positive individuals from the clinical cohort, 20 (48%; 95% confidence interval [CI], 32%-64%) fulfilled National Institutes of Health (NIH) NF1 diagnostic criteria based on the presence of more than 5 CALMs with or without freckling or an NF1-compatible family history. None of the 42 SPRED1-positive individuals (0%; 95% CI, 0%-7%) had discrete cutaneous or plexiform neurofibromas, typical NF1 osseous lesions, or symptomatic optic pathway gliomas. In the anonymous cohort of 1318 individuals, 34 different SPRED1 mutations in 43 probands were identified: 27 pathogenic mutations in 34 probands and 7 probable nonpathogenic missense mutations in 9 probands. Of 94 probands with familial CALMs with or without freckling and no other NF1 features, 69 (73%; 95% CI, 63%-80%) had an NF1 mutation and 18 (19%; 95% CI, 12%-29%) had a pathogenic SPRED1 mutation. In the anonymous cohort, 1.9% (95% CI, 1.2%-2.9%) of individuals with the clinical diagnosis of NF1 according to the NIH criteria had NFLS. CONCLUSIONS: A high SPRED1 mutation detection rate was found in NF1 mutation-negative families with an autosomal dominant phenotype of CALMs with or without freckling and no other NF1 features. Among individuals in this study, NFLS was not associated with the peripheral and central nervous system tumors seen in NF1.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

November 18, 2009

Volume

302

Issue

19

Start / End Page

2111 / 2118

Location

United States

Related Subject Headings

  • Young Adult
  • Syndrome
  • Phenotype
  • Neurofibromatosis 1
  • Mutation, Missense
  • Mutation
  • Middle Aged
  • Membrane Proteins
  • Male
  • Intracellular Signaling Peptides and Proteins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Messiaen, L., Yao, S., Brems, H., Callens, T., Sathienkijkanchai, A., Denayer, E., … Legius, E. (2009). Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA, 302(19), 2111–2118. https://doi.org/10.1001/jama.2009.1663
Messiaen, Ludwine, Suxia Yao, Hilde Brems, Tom Callens, Achara Sathienkijkanchai, Ellen Denayer, Emily Spencer, et al. “Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.JAMA 302, no. 19 (November 18, 2009): 2111–18. https://doi.org/10.1001/jama.2009.1663.
Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA. 2009 Nov 18;302(19):2111–8.
Messiaen, Ludwine, et al. “Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.JAMA, vol. 302, no. 19, Nov. 2009, pp. 2111–18. Pubmed, doi:10.1001/jama.2009.1663.
Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, Spencer E, Arn P, Babovic-Vuksanovic D, Bay C, Bobele G, Cohen BH, Escobar L, Eunpu D, Grebe T, Greenstein R, Hachen R, Irons M, Kronn D, Lemire E, Leppig K, Lim C, McDonald M, Narayanan V, Pearn A, Pedersen R, Powell B, Shapiro LR, Skidmore D, Tegay D, Thiese H, Zackai EH, Vijzelaar R, Taniguchi K, Ayada T, Okamoto F, Yoshimura A, Parret A, Korf B, Legius E. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA. 2009 Nov 18;302(19):2111–2118.
Journal cover image

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

November 18, 2009

Volume

302

Issue

19

Start / End Page

2111 / 2118

Location

United States

Related Subject Headings

  • Young Adult
  • Syndrome
  • Phenotype
  • Neurofibromatosis 1
  • Mutation, Missense
  • Mutation
  • Middle Aged
  • Membrane Proteins
  • Male
  • Intracellular Signaling Peptides and Proteins